Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine
Authors:
- Rachelle S. DoodyRDRachelle S. Doody
- David S. GeldmacherDGDavid S. Geldmacher
- Martin R. FarlowMFMartin R. Farlow
- Yijun SunYSYijun Sun
- Margaret MolineMMMargaret Moline
- Joan MackellJMJoan Mackell
- 10 May 2012
- journal article
- research article
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 33 (2-3) , 164-173
Abstract
Background/Aims: A large multicenter trial of donepezil 23 mg/day versus donepezil 10 mg/day for moderate-to-severe Alzheimer’s disease allowed patients taking concomitant memantine. We evaluated the efficacy/safety of donepezil 23 and 10 mg/day in this trial, with respect to concomitant memantine use. Methods: Prespecified analysis of data from a 24-week, randomized, double-blind trial. Patients were randomized to donepezil doses (23 vs. 10 mg/day) and stratified by concomitant memantine use (yes or no). Efficacy and safety were assessed for each donepezil dose in subgroups taking or not taking concomitant memantine. Results: At week 24, donepezil 23 mg/day provided significant cognitive benefits over 10 mg/day (p < 0.01) on the Severe Impairment Battery, with or without concomitant memantine (ANCOVA adjusted for baseline score, country and treatment). The higher dose showed no benefit on the global function, Mini-Mental State Examination or activities of daily living measures in either memantine subgroup. Rates of treatment-emergent adverse events (AEs) were higher for donepezil 23 mg/day with memantine (80.7%) than 23 mg/day without memantine (69.7%) or 10 mg/day with/without memantine (66.7/62.0%); across all treatment groups, most events were mild/moderate in severity. Individual rates of serious AEs were low (<1.0%), regardless of concomitant memantine use. Conclusion: In this population, concomitant memantine use did not alter the response profile of donepezil 23 vs. 10 mg/day. Donepezil 23 mg was generally safe and well tolerated among patients receiving donepezil alone and among patients receiving a combination of donepezil and memantine therapy.Keywords
This publication has 12 references indexed in Scilit:
- Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind studyClinical Therapeutics, 2010
- Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Long-term Course and Effectiveness of Combination Therapy in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2008
- Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing ExpectationsDementia and Geriatric Cognitive Disorders, 2008
- Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical SettingDementia and Geriatric Cognitive Disorders, 2006
- Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil TreatmentAlzheimer Disease & Associated Disorders, 2006
- Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease Patients Already Receiving DonepezilAlzheimer Disease & Associated Disorders, 2006
- Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatmentNeurology, 2006
- Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and DonepezilAnnals of Pharmacotherapy, 2004
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004